Current Movers: Corning Inc. (GLW), Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals Inc

Current Movers: Corning Inc. (GLW), Agios Pharmaceuticals, Inc. (AGIO)

The share price of Agios Pharmaceuticals, Inc. Capital International Ltd. CA now owns 344,137 shares of the biopharmaceutical company's stock valued at $14,361,000 after buying an additional 81,337 shares during the period. Baker BROS. Advisors LP purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at approximately $10,982,000. (AGIO). These ratios are important while doing valuation of the company or the shares of the company. Last month, Lewis Clayton Cantley, a Director at AGIO sold 1,018 shares for a total of $54,880. The Columbus Hill Capital Management Lp holds 611,194 shares with $21.89M value, down from 802,539 last quarter.

08/08/2016 - Agios Pharmaceuticals, Inc. had its "neutral" rating reiterated by analysts at Goldman Sachs.

Office Depot, Inc. (NASDAQ:ODP) share price increased in the last trading session with a previous 52-week high of $7.32. On the other end, a stock with a score from 0-2 would be viewed as weak. Latest closing price was 4.58% above its 50-day moving average and 17.48% above its 200-day moving average.

Corning Inc. has 1 year price target of $27. Agios Pharmaceuticals's revenue for the quarter was up 264.5% compared to the same quarter a year ago.

The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.51) by $0.17. For the Current Quarter, 10 analysts are projecting the mean EPS to be $-2.01/share. The company's revenue was up 264.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.08) earnings per share.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of USA & global copyright & trademark laws. Zacks Investment Research downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. The research firm, a subsidiary of Accern, identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time.

1/17/2017-CIBC Upgrade from a "Market Perform " rating to a " Outperform" rating.

Sell-side analyst recommendations point to a short term price target of $4.79 on the shares of Office Depot, Inc.

05/18/2016 - Agios Pharmaceuticals, Inc. had its " rating reiterated by analysts at Credit Suisse. It opened the session with a $4.71 price tag, later ranging from $4.68 to $4.89, the range at which the stock has traded at throughout the day. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. The company has an average rating of "Buy" and a consensus target price of $63.54. They now have a Dollars 135 price target on the stock. The company's 5 year Earnings per share growth and Capital Spending growth remains at 0 and 39.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The shares were sold at an average price of $58.62, for a total transaction of $175,860.00. The number of shares now owned by investors are 42.23 mln. The stock had a trading volume of 4,111,060 shares.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock.

06/13/2016 - Agios Pharmaceuticals, Inc. was upgraded to " by analysts at JP Morgan. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company's cancer product candidates are enasidenib and ivosidenib, which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Latest News